Combinational strategies of immunotherapy for hepatocellular carcinoma: One institutional experience in Taiwan.

e15684Background: Nivolumab in CheckMate40 study for advanced HCC has brought ORR 15 to 20% and DCR 55%. Our goup found lymph node or lung metastasis responded better and increased PDL1 expression ...